首页 > 最新文献

Alzheimer's & Dementia最新文献

英文 中文
Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories 血浆生物标志物进展跨越阿尔茨海默病淀粉样蛋白和tau正电子发射断层扫描轨迹
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-09 DOI: 10.1002/alz.71145
Rodrigo Cánovas, Christopher J. Fowler, Azadeh Feizpour, Vincent Dóre, Pierrick Bourgeat, Ziad S. Saad, Gallen Triana-Baltzer, Hartmuth C. Kolb, Manu Vandijck, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Jurgen Fripp, Simon Laws, Anthony W. Bannon, Kaj Blennow, Henrik Zetterberg, Stephanie Rainey-Smith, Sulantha Mathotaarachchi, Christopher C. Rowe, Colin L. Masters, James D. Doecke
With increased uptake in disease-modifying treatments for amyloid beta (Aβ) removal, it is important to measure performance of highly sensitive plasma biomarkers to detect the presence of Aβ and tau in cognitively impaired populations.
随着淀粉样蛋白(Aβ)去除的疾病改善治疗的增加,测量高灵敏度血浆生物标志物的性能以检测认知障碍人群中Aβ和tau的存在是很重要的。
{"title":"Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories","authors":"Rodrigo Cánovas, Christopher J. Fowler, Azadeh Feizpour, Vincent Dóre, Pierrick Bourgeat, Ziad S. Saad, Gallen Triana-Baltzer, Hartmuth C. Kolb, Manu Vandijck, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Jurgen Fripp, Simon Laws, Anthony W. Bannon, Kaj Blennow, Henrik Zetterberg, Stephanie Rainey-Smith, Sulantha Mathotaarachchi, Christopher C. Rowe, Colin L. Masters, James D. Doecke","doi":"10.1002/alz.71145","DOIUrl":"https://doi.org/10.1002/alz.71145","url":null,"abstract":"With increased uptake in disease-modifying treatments for amyloid beta (Aβ) removal, it is important to measure performance of highly sensitive plasma biomarkers to detect the presence of Aβ and tau in cognitively impaired populations.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"73 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146146298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The influence of midlife morbidity clusters on dementia risk: The ARIC study 中年发病群对痴呆风险的影响:ARIC研究
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-09 DOI: 10.1002/alz.71110
Elise Kinyanjui, Renee C. Groechel, Valerie Morrill, Keenan A. Walker, Anna M. Kucharska-Newton, Thomas H. Mosley, Silvia Koton, David S. Knopman, Jordan Weiss, Rebecca F. Gottesman, Marco Egle
Understanding comorbidities’ combined impacts on dementia risk may offer a more comprehensive understanding of individuals’ risk. Using machine-learning, we grouped individuals with similar midlife risk profiles into clusters and explored associations with dementia risk.
了解合并症对痴呆风险的综合影响可以更全面地了解个体的风险。使用机器学习,我们将具有相似中年风险概况的个体分组,并探索与痴呆风险的关联。
{"title":"The influence of midlife morbidity clusters on dementia risk: The ARIC study","authors":"Elise Kinyanjui, Renee C. Groechel, Valerie Morrill, Keenan A. Walker, Anna M. Kucharska-Newton, Thomas H. Mosley, Silvia Koton, David S. Knopman, Jordan Weiss, Rebecca F. Gottesman, Marco Egle","doi":"10.1002/alz.71110","DOIUrl":"https://doi.org/10.1002/alz.71110","url":null,"abstract":"Understanding comorbidities’ combined impacts on dementia risk may offer a more comprehensive understanding of individuals’ risk. Using machine-learning, we grouped individuals with similar midlife risk profiles into clusters and explored associations with dementia risk.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"45 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146146295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Community perspectives on epigenetic dementia risk testing: Willingness, implementation preferences, and reasons for not testing in midlife and older adults 社区对表观遗传痴呆风险检测的看法:在中年和老年人中不进行检测的意愿、实施偏好和原因
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-06 DOI: 10.1002/alz.71094
Deirdre M. O'Shea, Devi Dhanekula, Swati Kumar, Lily Wang, Lisa Wiese, Tatjana Rundek, James E. Galvin
INTRODUCTION Epigenetic assays may support non‐invasive dementia risk stratification; community views on willingness and implementation remain under‐characterized. METHODS In a survey of 425 adults ≥50 years old, we assessed the willingness for a hypothetical epigenetic test, implementation preferences, reactions to a high‐risk result, behavior‐change intentions, and reasons for not testing using multivariable models. RESULTS Overall, 82.1% showed a willingness. Health literacy (odds ratio [OR] = 2.61) and Alzheimer's disease (AD) concern (OR = 2.06) increased that willingness; doctor dependence decreased it (OR = 0.62). The top drivers were perceived to be accuracy and speed. The preferred modality was a combination of biomarker and cognitive over biomarker‐only. Intended changes prioritized alcohol reduction, then diet, exercise, cognitive activity. Risk worry and insurance concerns exceeded stigma; higher literacy related to lower stigma, and epigenetics familiarity and AD worry related to higher insurance concern. The reasons for not testing were data privacy/accuracy concerns, logistics/costs, and needles. DISCUSSION Findings support emphasizing test accuracy, turnaround, and governance/legal information when implementing DNAm testing for dementia risk.
表观遗传学分析可能支持非侵入性痴呆风险分层;社区对意愿和实施的看法仍不明确。方法在一项对425名≥50岁的成年人的调查中,我们评估了假设表观遗传测试的意愿、实施偏好、对高风险结果的反应、行为改变意图以及不使用多变量模型进行测试的原因。结果总体而言,82.1%的受访者表示愿意。健康素养(比值比[OR] = 2.61)和对阿尔茨海默病(AD)的关注(OR = 2.06)增加了这种意愿;对医生的依赖使其降低(OR = 0.62)。人们认为最重要的驱动因素是准确性和速度。首选的方式是生物标志物和认知的结合,而不是仅仅生物标志物。预期的改变首先是减少饮酒,然后是饮食、锻炼和认知活动。风险担忧和保险担忧超过了耻辱;较高的文化素养与较低的耻辱感有关,而表观遗传学熟悉度和阿尔茨海默病担忧与较高的保险担忧有关。不测试的原因是数据隐私/准确性问题、物流/成本和针头。研究结果支持在实施痴呆症风险的DNAm测试时强调测试准确性、周转时间和治理/法律信息。
{"title":"Community perspectives on epigenetic dementia risk testing: Willingness, implementation preferences, and reasons for not testing in midlife and older adults","authors":"Deirdre M. O'Shea, Devi Dhanekula, Swati Kumar, Lily Wang, Lisa Wiese, Tatjana Rundek, James E. Galvin","doi":"10.1002/alz.71094","DOIUrl":"https://doi.org/10.1002/alz.71094","url":null,"abstract":"INTRODUCTION Epigenetic assays may support non‐invasive dementia risk stratification; community views on willingness and implementation remain under‐characterized. METHODS In a survey of 425 adults ≥50 years old, we assessed the willingness for a hypothetical epigenetic test, implementation preferences, reactions to a high‐risk result, behavior‐change intentions, and reasons for not testing using multivariable models. RESULTS Overall, 82.1% showed a willingness. Health literacy (odds ratio [OR] = 2.61) and Alzheimer's disease (AD) concern (OR = 2.06) increased that willingness; doctor dependence decreased it (OR = 0.62). The top drivers were perceived to be accuracy and speed. The preferred modality was a combination of biomarker and cognitive over biomarker‐only. Intended changes prioritized alcohol reduction, then diet, exercise, cognitive activity. Risk worry and insurance concerns exceeded stigma; higher literacy related to lower stigma, and epigenetics familiarity and AD worry related to higher insurance concern. The reasons for not testing were data privacy/accuracy concerns, logistics/costs, and needles. DISCUSSION Findings support emphasizing test accuracy, turnaround, and governance/legal information when implementing DNAm testing for dementia risk.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"34 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146122141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns 蛋白质组学揭示了阿尔茨海默病具有不同进展模式的三种分子亚型
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-06 DOI: 10.1002/alz.71106
Xiao-He Hou, Wei Zhang, Kairan Kang, Yifei Jin, Peng Ren, Linbo Wang, Zeyu Li, Yuzhu Li, Jia You, Bei Zhang, Qing Ma, , Fang Xie, Jin-Tai Yu, Jian-Feng Feng, Wei Cheng
Alzheimer's disease (AD) shows marked molecular heterogeneity. Defining biological subtypes may refine diagnosis and treatment.
阿尔茨海默病(AD)表现出明显的分子异质性。确定生物学亚型可以改善诊断和治疗。
{"title":"Proteomics reveals three molecular subtypes of Alzheimer's disease with distinct progression patterns","authors":"Xiao-He Hou, Wei Zhang, Kairan Kang, Yifei Jin, Peng Ren, Linbo Wang, Zeyu Li, Yuzhu Li, Jia You, Bei Zhang, Qing Ma, , Fang Xie, Jin-Tai Yu, Jian-Feng Feng, Wei Cheng","doi":"10.1002/alz.71106","DOIUrl":"https://doi.org/10.1002/alz.71106","url":null,"abstract":"Alzheimer's disease (AD) shows marked molecular heterogeneity. Defining biological subtypes may refine diagnosis and treatment.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"17 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146129272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial heterogeneity in microglia-complement crosstalk: Implications for synaptic pruning in Alzheimer's disease 小胶质-补体串扰的空间异质性:阿尔茨海默病突触修剪的含义
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-05 DOI: 10.1002/alz.71185
Qiuyan Ye, Wei Gao, Jiaping Feng, Xue Li, Jianhui Li, Fengge Yang, Linqing Li, Mingsheng Zi, Xinkai Wu, Hainan Gao, Honglin Li
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by synaptic loss, as a key pathological feature in its early stages. Recent studies have highlighted the central role of microglia–complement interactions in synaptic pruning. This interaction exhibits significant spatial heterogeneity in AD, with activation patterns and functional manifestations varying across different brain regions and stages of disease. Therefore, this article systematically reviews the synergistic mechanisms of microglia and the complement system in physiological synaptic pruning. Additionally, the dynamic evolution of the complement–immune network during disease progression is analyzed, and the amplifying effect of genetic factors on the spatial heterogeneity of synaptic pruning is explored. Furthermore, current treatment strategies from both Western medicine and traditional Chinese medicine are discussed, emphasizing the potential value of combining these approaches for intervening in synaptic loss in AD.
阿尔茨海默病(AD)是一种以突触丧失为特征的神经退行性疾病,是其早期的一个关键病理特征。最近的研究强调了小胶质细胞-补体相互作用在突触修剪中的核心作用。这种相互作用在阿尔茨海默病中表现出显著的空间异质性,在不同的大脑区域和疾病阶段,激活模式和功能表现各不相同。因此,本文就小胶质细胞与补体系统在生理突触修剪中的协同作用机制作一系统综述。此外,还分析了补体-免疫网络在疾病进展过程中的动态演化,并探讨了遗传因素对突触修剪空间异质性的放大效应。此外,本文还讨论了目前西医和中医的治疗策略,强调了结合这些方法干预阿尔茨海默病突触丧失的潜在价值。
{"title":"Spatial heterogeneity in microglia-complement crosstalk: Implications for synaptic pruning in Alzheimer's disease","authors":"Qiuyan Ye, Wei Gao, Jiaping Feng, Xue Li, Jianhui Li, Fengge Yang, Linqing Li, Mingsheng Zi, Xinkai Wu, Hainan Gao, Honglin Li","doi":"10.1002/alz.71185","DOIUrl":"https://doi.org/10.1002/alz.71185","url":null,"abstract":"Alzheimer's disease (AD) is a neurodegenerative disorder characterized by synaptic loss, as a key pathological feature in its early stages. Recent studies have highlighted the central role of microglia–complement interactions in synaptic pruning. This interaction exhibits significant spatial heterogeneity in AD, with activation patterns and functional manifestations varying across different brain regions and stages of disease. Therefore, this article systematically reviews the synergistic mechanisms of microglia and the complement system in physiological synaptic pruning. Additionally, the dynamic evolution of the complement–immune network during disease progression is analyzed, and the amplifying effect of genetic factors on the spatial heterogeneity of synaptic pruning is explored. Furthermore, current treatment strategies from both Western medicine and traditional Chinese medicine are discussed, emphasizing the potential value of combining these approaches for intervening in synaptic loss in AD.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"117 1","pages":""},"PeriodicalIF":14.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146115813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From consortia discovery to biotech creation: An innovative approach to next-gen Alzheimer's drugs. 从联合发现到生物技术创造:新一代阿尔茨海默病药物的创新方法。
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/alz.71165
Sarah F Giardina,Alexander Culver,Chandrama Ahmed,Christian Mirescu,Adrian L Oblak,Jared Brosch,W Brent Clayton,Jeffrey L Dage,Bruce T Lamb,Timothy I Richardson,Derek Small,Alan D Palkowitz
Alzheimer's disease (AD) research has entered a new era where public-private partnerships are reigniting the pursuit of disease-modifying therapies targeting mechanisms beyond amyloid and tau. This perspective outlines how Monument Biosciences was founded to advance novel therapies by translating National Institutes of Health (NIH) -supported discoveries from the TaRget Enablement to Accelerate Therapy Development for AD (TREAT-AD) and the Model Organism Development and Evaluation for Late-onset AD (MODEL-AD) consortia into a venture-backed pipeline focused on neuroinflammation. Monument Bio strategically builds on genetic validation and high-quality, nondilutive-funded research and serves as a case study in how academic research can reduce risk in early-stage biotech development to advance novel therapies. The company exemplifies a novel academic-startup collaboration model, emphasizing robust biomarker strategies to streamline clinical development. Aligned with the framework presented by Richardson et al., in this issue, this approach supports a new generation of neuroscience companies grounded in open science, strong target validation, and disease-relevant endpoints. HIGHLIGHTS: The Alzheimer's field is poised for next-generation therapies beyond amyloid and tau. Monument Bio translates National Institutes of Health (NIH)-supported science into a venture-backed Alzheimer's pipeline. TaRget Enablement to Accelerate Therapy Development for AD (TREAT-AD) and Model Organism Development and Evaluation for Late-onset AD (MODEL-AD) de-risk programs with validated assays, probes, and biomarker tools. Monument Bio shows how TREAT-AD's Target Enabling Packages (TEPs) enable difficult targets. Integrated biomarkers enable predictive translation, faster approval, and investment rationale.
阿尔茨海默病(AD)研究进入了一个新的时代,公私合作伙伴关系重新点燃了对针对淀粉样蛋白和tau蛋白以外机制的疾病修饰疗法的追求。这一观点概述了纪念碑生物科学公司是如何通过将美国国立卫生研究院(NIH)支持的发现转化为加速阿尔茨海默病治疗开发(TREAT-AD)和迟发性阿尔茨海默病模型生物开发和评估(Model -AD)联盟的新疗法来推进新疗法的。Monument Bio在战略上建立在基因验证和高质量、非稀释资助的研究基础上,并作为学术研究如何降低早期生物技术开发风险以推进新疗法的案例研究。该公司体现了一种新颖的学术与创业合作模式,强调强大的生物标志物战略,以简化临床开发。与理查森等人在本期提出的框架一致,该方法支持新一代基于开放科学、强有力的目标验证和疾病相关终点的神经科学公司。重点:阿尔茨海默氏症领域已准备好开发淀粉样蛋白和tau蛋白以外的下一代治疗方法。Monument Bio将美国国立卫生研究院(NIH)支持的科学转化为风险投资支持的阿尔茨海默病管道。通过验证的检测、探针和生物标志物工具,加速阿尔茨海默病(AD)治疗方法的开发和晚发型阿尔茨海默病(AD)模型生物的开发和评估。Monument Bio展示了TREAT-AD的目标激活包(TEPs)如何实现困难的目标。集成的生物标志物可实现预测翻译,更快的审批和投资理由。
{"title":"From consortia discovery to biotech creation: An innovative approach to next-gen Alzheimer's drugs.","authors":"Sarah F Giardina,Alexander Culver,Chandrama Ahmed,Christian Mirescu,Adrian L Oblak,Jared Brosch,W Brent Clayton,Jeffrey L Dage,Bruce T Lamb,Timothy I Richardson,Derek Small,Alan D Palkowitz","doi":"10.1002/alz.71165","DOIUrl":"https://doi.org/10.1002/alz.71165","url":null,"abstract":"Alzheimer's disease (AD) research has entered a new era where public-private partnerships are reigniting the pursuit of disease-modifying therapies targeting mechanisms beyond amyloid and tau. This perspective outlines how Monument Biosciences was founded to advance novel therapies by translating National Institutes of Health (NIH) -supported discoveries from the TaRget Enablement to Accelerate Therapy Development for AD (TREAT-AD) and the Model Organism Development and Evaluation for Late-onset AD (MODEL-AD) consortia into a venture-backed pipeline focused on neuroinflammation. Monument Bio strategically builds on genetic validation and high-quality, nondilutive-funded research and serves as a case study in how academic research can reduce risk in early-stage biotech development to advance novel therapies. The company exemplifies a novel academic-startup collaboration model, emphasizing robust biomarker strategies to streamline clinical development. Aligned with the framework presented by Richardson et al., in this issue, this approach supports a new generation of neuroscience companies grounded in open science, strong target validation, and disease-relevant endpoints. HIGHLIGHTS: The Alzheimer's field is poised for next-generation therapies beyond amyloid and tau. Monument Bio translates National Institutes of Health (NIH)-supported science into a venture-backed Alzheimer's pipeline. TaRget Enablement to Accelerate Therapy Development for AD (TREAT-AD) and Model Organism Development and Evaluation for Late-onset AD (MODEL-AD) de-risk programs with validated assays, probes, and biomarker tools. Monument Bio shows how TREAT-AD's Target Enabling Packages (TEPs) enable difficult targets. Integrated biomarkers enable predictive translation, faster approval, and investment rationale.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"1 1 1","pages":"e71165"},"PeriodicalIF":14.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An MRI-based macro- and microstructural neuroimaging-wide association study of subsequent cognitive impairment. 一项基于mri的宏观和微观结构神经成像与继发性认知障碍的关联研究。
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/alz.71135
Tugce Duran, Murat Bilgel, Yang An, Sridhar Kandala, Christos Davatzikos, Bennett A Landman, Guray Erus, Abhay Moghekar, Luigi Ferrucci, Keenan A Walker, Susan M Resnick

Introduction: This study longitudinally examined 154 magnetic resonance imaging (MRI) biomarkers in cognitively normal (CN) individuals to identify structural brain changes most strongly associated with subsequent cognitive impairment (SI).

Methods: We analyzed 509 Baltimore Longitudinal Study of Aging participants (age ≥ 50, CN at baseline) with longitudinal cognitive and 3T MRI (T1/T2-weighted scans and diffusion tensor imaging) data. MRI biomarker associations with SI status were analyzed, adjusting for confounders and stratifying by sex and amyloid beta (Aβ) status.

Results: Participants who developed SI over 4.6 years' follow-up showed greater longitudinal changes in white matter (WM) integrity, particularly in the corpus callosum, cingulum bundle, and inferior fronto-occipital fasciculus, compared to CN-stable. To a lesser degree, we also observed temporal thinning and atrophy linked to SI. These associations were amplified among males and amyloid-positive individuals.

Discussion: Longitudinal alterations in WM microstructural integrity were most strongly associated with future impairment, highlighting the importance of early WM changes in the development of MCI and dementia.

本研究纵向检查了154个认知正常(CN)个体的磁共振成像(MRI)生物标志物,以确定与随后的认知障碍(SI)最密切相关的脑结构变化。方法:我们分析了509名巴尔的摩纵向研究老年参与者(年龄≥50岁,基线时CN)的纵向认知和3T MRI (T1/ t2加权扫描和扩散张量成像)数据。分析MRI生物标志物与SI状态的关联,调整混杂因素并按性别和β淀粉样蛋白(Aβ)状态分层。结果:在4.6年的随访中,发生SI的参与者在白质(WM)完整性方面表现出更大的纵向变化,特别是在胼胝体、扣带束和额枕下束,与cn -稳定相比。在较小程度上,我们还观察到与SI相关的颞叶变薄和萎缩。这些关联在男性和淀粉样蛋白阳性个体中更为明显。讨论:WM微结构完整性的纵向改变与未来的损伤密切相关,突出了早期WM变化在MCI和痴呆发展中的重要性。
{"title":"An MRI-based macro- and microstructural neuroimaging-wide association study of subsequent cognitive impairment.","authors":"Tugce Duran, Murat Bilgel, Yang An, Sridhar Kandala, Christos Davatzikos, Bennett A Landman, Guray Erus, Abhay Moghekar, Luigi Ferrucci, Keenan A Walker, Susan M Resnick","doi":"10.1002/alz.71135","DOIUrl":"10.1002/alz.71135","url":null,"abstract":"<p><strong>Introduction: </strong>This study longitudinally examined 154 magnetic resonance imaging (MRI) biomarkers in cognitively normal (CN) individuals to identify structural brain changes most strongly associated with subsequent cognitive impairment (SI).</p><p><strong>Methods: </strong>We analyzed 509 Baltimore Longitudinal Study of Aging participants (age ≥ 50, CN at baseline) with longitudinal cognitive and 3T MRI (T1/T2-weighted scans and diffusion tensor imaging) data. MRI biomarker associations with SI status were analyzed, adjusting for confounders and stratifying by sex and amyloid beta (Aβ) status.</p><p><strong>Results: </strong>Participants who developed SI over 4.6 years' follow-up showed greater longitudinal changes in white matter (WM) integrity, particularly in the corpus callosum, cingulum bundle, and inferior fronto-occipital fasciculus, compared to CN-stable. To a lesser degree, we also observed temporal thinning and atrophy linked to SI. These associations were amplified among males and amyloid-positive individuals.</p><p><strong>Discussion: </strong>Longitudinal alterations in WM microstructural integrity were most strongly associated with future impairment, highlighting the importance of early WM changes in the development of MCI and dementia.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 2","pages":"e71135"},"PeriodicalIF":11.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Care preferences for persons with cognitive impairment: A discrete choice experiment. 认知障碍患者的护理偏好:一个离散选择实验。
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/alz.71107
Dean A Regier, Jean O Taylor, Astoria Ho, Soo Borson, Anne M Turner

Introduction: Evidence is limited on preferences of persons with cognitive decline and their care partners (CPs) regarding care. Our aim was to identify preferences and preference evolution for transitions in supportive care.

Methods: We conducted a discrete choice experiment (DCE) (repeated measures baseline, 6-months) with older adults with mild cognitive impairment or mild to moderate dementia and CPs. Tasks were anchored to health states describing progressive memory and function decline. Split-sample mixed logit models estimated part-worth utilities.

Results: Baseline DCEs were completed by 131 cognitively impaired older adults and 137 CPs; 118 and 132 completed 6-month DCEs. At both timepoints, respondents preferred in-home care with moderate support when considering moderate or severe cognitive impairment. As impairment worsened, the acceptability of assisted living increased, especially among CPs.

Discussion: Persons with cognitive decline engaged in future-oriented decisions. Preferences were stable across time for both samples, and assisted living was more acceptable for CPs.

关于认知衰退患者及其护理伙伴(CPs)对护理的偏好的证据有限。我们的目的是确定支持治疗过渡的偏好和偏好演变。方法:我们对患有轻度认知障碍或轻中度痴呆和CPs的老年人进行了离散选择实验(DCE)(重复测量基线,6个月)。任务被固定在描述渐进记忆和功能衰退的健康状态上。分样本混合logit模型估计部分价值公用事业。结果:131名认知障碍老年人和137名CPs完成了基线dce;118和132完成了6个月的dce。在这两个时间点,当考虑到中度或重度认知障碍时,受访者更倾向于有中等支持的家庭护理。随着损伤的恶化,辅助生活的可接受性增加,特别是在CPs中。讨论:认知能力下降的人从事面向未来的决策。随着时间的推移,两个样本的偏好都是稳定的,CPs更容易接受辅助生活。
{"title":"Care preferences for persons with cognitive impairment: A discrete choice experiment.","authors":"Dean A Regier, Jean O Taylor, Astoria Ho, Soo Borson, Anne M Turner","doi":"10.1002/alz.71107","DOIUrl":"10.1002/alz.71107","url":null,"abstract":"<p><strong>Introduction: </strong>Evidence is limited on preferences of persons with cognitive decline and their care partners (CPs) regarding care. Our aim was to identify preferences and preference evolution for transitions in supportive care.</p><p><strong>Methods: </strong>We conducted a discrete choice experiment (DCE) (repeated measures baseline, 6-months) with older adults with mild cognitive impairment or mild to moderate dementia and CPs. Tasks were anchored to health states describing progressive memory and function decline. Split-sample mixed logit models estimated part-worth utilities.</p><p><strong>Results: </strong>Baseline DCEs were completed by 131 cognitively impaired older adults and 137 CPs; 118 and 132 completed 6-month DCEs. At both timepoints, respondents preferred in-home care with moderate support when considering moderate or severe cognitive impairment. As impairment worsened, the acceptability of assisted living increased, especially among CPs.</p><p><strong>Discussion: </strong>Persons with cognitive decline engaged in future-oriented decisions. Preferences were stable across time for both samples, and assisted living was more acceptable for CPs.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 2","pages":"e71107"},"PeriodicalIF":11.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12865324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging genetic propensity to identify modifiable factors for the age at onset of Alzheimer's disease. 利用遗传倾向来确定阿尔茨海默病发病年龄的可改变因素。
IF 11.1 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/alz.71111
Yi-Ju Li, Jong Ok La, Adam Naj, Eden R Martin

Introduction: Knowledge of modifiable factors influencing age at onset (AAO) of Alzheimer's disease (AD) remains limited. This study utilizes genetic information to uncover such factors.

Methods: Using 43 exposure genome-wide association studies (GWAS) summary statistics, we calculated corresponding polygenic scores (PGS) for 9219 AD cases and 10,345 controls from the Alzheimer's Disease Genetic Consortium (ADGC). Linear mixed model and survival analyses were performed to identify exposure-PGS associated with AAO. Top exposures were cross-evaluated using PGS from the PGS Catalog and Mendelian randomization (MR) for causal relationships.

Results: Eight exposures showed significant exposure-PGS associations with AAO of AD. Higher educational attainment, better cognitive performance, and greater relative fat intake were associated with later AAO; whereas the remaining were linked to earlier onset. MR analysis indicated a causal relationship between AAO and educational attainment, cardiovascular disease, and type 2 diabetes (T2D).

Discussion: The eight modifiable factors, particularly educational attainment, cardiovascular disease, and T2D, may facilitate early intervention to delay the onset of AD.

Highlights: We screened 43 modifiable factors for their association with the age at onset (AAO) of Alzheimer's disease (AD) using polygenic scores (PGS) as the proxy for the exposure. Higher educational attainment, better cognitive performance, and greater relative fat intake were linked to later AAO, suggesting an enhanced resilience against AD. Type 2 diabetes, cardiovascular disease, major coronary heart disease, and increased low-density lipoprotein (LDL) -cholesterol and total cholesterol are associated with earlier AAO. Mendelian randomization analysis revealed causal effects of educational attainment, type 2 diabetes, and cardiovascular disease on AAO of AD.

对阿尔茨海默病(AD)发病年龄(AAO)的可改变因素的了解仍然有限。这项研究利用遗传信息来揭示这些因素。方法:利用43项暴露全基因组关联研究(GWAS)汇总统计数据,计算来自阿尔茨海默病遗传联盟(ADGC)的9219例AD病例和10345例对照的相应多基因评分(PGS)。采用线性混合模型和生存分析来确定暴露- pgs与AAO的相关性。使用PGS目录中的PGS和孟德尔随机化(MR)进行因果关系交叉评估最高暴露。结果:8次暴露显示暴露- pgs与AD的AAO显著相关。较高的受教育程度、较好的认知能力和较高的相对脂肪摄入量与晚期AAO相关;而其余的则与早期发病有关。MR分析显示AAO与受教育程度、心血管疾病和2型糖尿病(T2D)之间存在因果关系。讨论:八个可改变的因素,特别是受教育程度、心血管疾病和T2D,可能有助于早期干预以延缓AD的发病。重点:我们筛选了43个与阿尔茨海默病(AD)发病年龄(AAO)相关的可改变因素,使用多基因评分(PGS)作为暴露的代理。较高的教育程度、更好的认知能力和更多的相对脂肪摄入量与较晚的AAO有关,这表明对AD的抵抗力增强。2型糖尿病、心血管疾病、主要冠心病、低密度脂蛋白(LDL) -胆固醇和总胆固醇升高与早期AAO相关。孟德尔随机分析揭示了受教育程度、2型糖尿病和心血管疾病对AD AAO的因果影响。
{"title":"Leveraging genetic propensity to identify modifiable factors for the age at onset of Alzheimer's disease.","authors":"Yi-Ju Li, Jong Ok La, Adam Naj, Eden R Martin","doi":"10.1002/alz.71111","DOIUrl":"https://doi.org/10.1002/alz.71111","url":null,"abstract":"<p><strong>Introduction: </strong>Knowledge of modifiable factors influencing age at onset (AAO) of Alzheimer's disease (AD) remains limited. This study utilizes genetic information to uncover such factors.</p><p><strong>Methods: </strong>Using 43 exposure genome-wide association studies (GWAS) summary statistics, we calculated corresponding polygenic scores (PGS) for 9219 AD cases and 10,345 controls from the Alzheimer's Disease Genetic Consortium (ADGC). Linear mixed model and survival analyses were performed to identify exposure-PGS associated with AAO. Top exposures were cross-evaluated using PGS from the PGS Catalog and Mendelian randomization (MR) for causal relationships.</p><p><strong>Results: </strong>Eight exposures showed significant exposure-PGS associations with AAO of AD. Higher educational attainment, better cognitive performance, and greater relative fat intake were associated with later AAO; whereas the remaining were linked to earlier onset. MR analysis indicated a causal relationship between AAO and educational attainment, cardiovascular disease, and type 2 diabetes (T2D).</p><p><strong>Discussion: </strong>The eight modifiable factors, particularly educational attainment, cardiovascular disease, and T2D, may facilitate early intervention to delay the onset of AD.</p><p><strong>Highlights: </strong>We screened 43 modifiable factors for their association with the age at onset (AAO) of Alzheimer's disease (AD) using polygenic scores (PGS) as the proxy for the exposure. Higher educational attainment, better cognitive performance, and greater relative fat intake were linked to later AAO, suggesting an enhanced resilience against AD. Type 2 diabetes, cardiovascular disease, major coronary heart disease, and increased low-density lipoprotein (LDL) -cholesterol and total cholesterol are associated with earlier AAO. Mendelian randomization analysis revealed causal effects of educational attainment, type 2 diabetes, and cardiovascular disease on AAO of AD.</p>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"22 2","pages":"e71111"},"PeriodicalIF":11.1,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146140794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks. 长冠状动脉脉络膜丛改变及其与阿尔茨海默病风险的关系
IF 14 1区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2026-02-01 DOI: 10.1002/alz.71020
Huize Pang,Jennifer Frontera,Li Jiang,Chenyang Li,Allal Boutajangout,Zhe Sun,Ludovic Debure,Mobeena Ghuman,Alok Vedvyas,Arjun V Masurkar,Thomas Wisniewski,Yulin Ge
INTRODUCTIONChoroid plexus (ChP) enlargement is a neuroimaging biomarker of neuroinflammation and neurodegeneration. However, evidence of ChP structural and perfusion alterations in long coronavirus disease (COVID) and their clinical relevance remains limited.METHODSThis study included 86 long COVID, 67 recovered COVID, and 26 COVID-negative healthy controls (HCs). ChP volume and cerebral blood flow (CBF) were quantified, and their associations with Alzheimer's disease (AD) symptoms and plasma biomarkers were examined.RESULTSBoth patient groups showed higher ChP volume and lower CBF than HC. Relative to recovered COVID, long COVID patients had a larger ChP volume, but no significant difference in CBF. ChP volume correlated positively with glial fibrillary acidic protein (r = 0.35) and phosphorylated tau217 (p-tau217; r = 0.54), while CBF correlated negatively with p-tau217 (r = -0.56). Both ChP volume and CBF were associated with cognitive decline measured with Mini-Mental State Examination and Clinical Dementia Rating.DISCUSSIONThese findings suggest that ChP differences in long COVID are associated with AD-related cognitive decline and increased plasma biomarkers.HIGHLIGHTSLong coronavirus disease (COVID) patients show choroid plexus (ChP) enlargement and reduced cerebral blood flow. ChP alterations are associated with Alzheimer's disease (AD)-related symptoms and plasma biomarker changes. ChP alterations on magnetic resonance imaging may serve as imaging markers for tracking neurological symptoms and AD-related pathology in post-COVID patients.
脉络丛(ChP)扩大是神经炎症和神经退行性变的神经影像学生物标志物。然而,长冠状病毒病(COVID)中ChP结构和灌注改变及其临床相关性的证据仍然有限。方法纳入86例新冠肺炎患者、67例康复患者和26例新冠肺炎阴性健康对照。量化ChP体积和脑血流量(CBF),并检测其与阿尔茨海默病(AD)症状和血浆生物标志物的关系。结果两组患者ChP容积均高于HC, CBF均低于HC。与痊愈患者相比,长冠患者ChP体积较大,但CBF差异无统计学意义。ChP体积与胶质纤维酸性蛋白(r = 0.35)和磷酸化tau217 (p-tau217; r = 0.54)呈正相关,而CBF与p-tau217呈负相关(r = -0.56)。ChP容量和CBF均与认知能力下降有关,测量方法为迷你精神状态检查和临床痴呆评分。这些发现表明,长期COVID的ChP差异与ad相关的认知能力下降和血浆生物标志物增加有关。长冠状病毒病(COVID)患者表现为脉络膜丛(ChP)扩大和脑血流量减少。ChP改变与阿尔茨海默病(AD)相关症状和血浆生物标志物改变有关。磁共振成像ChP改变可作为追踪新冠肺炎后患者神经系统症状和ad相关病理的影像学指标。
{"title":"Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks.","authors":"Huize Pang,Jennifer Frontera,Li Jiang,Chenyang Li,Allal Boutajangout,Zhe Sun,Ludovic Debure,Mobeena Ghuman,Alok Vedvyas,Arjun V Masurkar,Thomas Wisniewski,Yulin Ge","doi":"10.1002/alz.71020","DOIUrl":"https://doi.org/10.1002/alz.71020","url":null,"abstract":"INTRODUCTIONChoroid plexus (ChP) enlargement is a neuroimaging biomarker of neuroinflammation and neurodegeneration. However, evidence of ChP structural and perfusion alterations in long coronavirus disease (COVID) and their clinical relevance remains limited.METHODSThis study included 86 long COVID, 67 recovered COVID, and 26 COVID-negative healthy controls (HCs). ChP volume and cerebral blood flow (CBF) were quantified, and their associations with Alzheimer's disease (AD) symptoms and plasma biomarkers were examined.RESULTSBoth patient groups showed higher ChP volume and lower CBF than HC. Relative to recovered COVID, long COVID patients had a larger ChP volume, but no significant difference in CBF. ChP volume correlated positively with glial fibrillary acidic protein (r = 0.35) and phosphorylated tau217 (p-tau217; r = 0.54), while CBF correlated negatively with p-tau217 (r = -0.56). Both ChP volume and CBF were associated with cognitive decline measured with Mini-Mental State Examination and Clinical Dementia Rating.DISCUSSIONThese findings suggest that ChP differences in long COVID are associated with AD-related cognitive decline and increased plasma biomarkers.HIGHLIGHTSLong coronavirus disease (COVID) patients show choroid plexus (ChP) enlargement and reduced cerebral blood flow. ChP alterations are associated with Alzheimer's disease (AD)-related symptoms and plasma biomarker changes. ChP alterations on magnetic resonance imaging may serve as imaging markers for tracking neurological symptoms and AD-related pathology in post-COVID patients.","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"132 4 1","pages":"e71020"},"PeriodicalIF":14.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146073328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Alzheimer's & Dementia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1